Kaneka Eurogentec Intelligence Profile

eurogentec.comLast reviewed: October 20, 2026Research coverage: 86%

Overall data confidence:Unknown

Identity confidence

High

8 of 10 identity fields independently documented

Corporate continuity

Continuity supported — domain registered 1999-01-05 for a company founded in 1985; the site carries current operational content, including General Terms amended 2025-10-14 and a June 2025 facility-expansion announcement

Based on domain history and corporate record fields

Regulatory exposure

None identified

Derived from published risk flags

Evidence integrity

High

6 of 7 testing fields documented

Transaction transparency

Moderate

3 of 5 commercial fields documented

Change activity

None tracked

0 change events tracked

Research Incomplete

Research coverage for this vendor is 86%. Our research on Kaneka Eurogentec remains incomplete — what we have verified so far is published below, and research is continuing.

Still to research:

Registration jurisdiction researched (state_of_registration)
Refund policy reviewed (refund_return_policy)
Payment methods reviewed (accepted_payment_methods)
Public summary reviewed

Overview#

Kaneka Eurogentec S.A. is a Belgian (Seraing/Liège) life-science manufacturer founded in 1985 and part of Japan's Kaneka Corporation since 2010 — a sibling, within the Kaneka group, of directory vendor AnaSpec, which is Eurogentec's U.S. subsidiary. FIT for this directory is confirmed on Eurogentec's own offering: it sells custom and catalog peptides and operates a GMP peptide-manufacturing/CDMO service (research grade under ISO 9001; GMP grade under 21 CFR 210/211), alongside its larger oligonucleotide, plasmid-DNA, mRNA and protein businesses. Corporate identity is the best-documented in this batch: Belgium's federal enterprise registry (enterprise 0427.348.346) confirms the legal name, public-limited-company form, Active status, 1985 start date and the Seraing registered seat, all matching the company's own terms of sale. Peptide QC documentation practice is described in detail (HPLC % peak area, MS identity, CoA for both grades; batch records and retained lot samples for GMP), though certificates are delivered with orders rather than posted publicly, and no dated public test results exist. All defined regulatory searches (FDA warning letters, recalls, import alerts, FTC, state AG, civil litigation, criminal/injunctive) returned No Record Found in the defined search; the company is an FDA/EMA-inspected CDMO, which is recorded as inspection history, not enforcement. Open items: the current U.S. registration status of any Eurogentec-branded U.S. entity (the San Diego subsidiary is documented historically; current U.S. peptide work runs through AnaSpec), accepted payment instruments, and the specific return clauses of the (published, versioned) terms of sale. No serious (High/Critical) findings.

Company Identity#

Vendor Brand NameKaneka Eurogentec

HighSource: Kaneka Eurogentec — General Terms & Conditions of Sale (brand/entity presentation)

Primary Website Domaineurogentec.com

ModerateSource: Kaneka Eurogentec — official website (intake domain confirmation)

Legal Entity NameKaneka Eurogentec S.A.

HighSource: Belgium Crossroads Bank for Enterprises (CBE) — registered entity data, enterprise 0427.348.346

State of RegistrationNot independently verified

UnknownSource: Belgium CBE — registered entity data (registered seat Seraing, Belgium)

Entity StatusActive — Belgian CBE registry shows Status: Active, legal situation: Normal situation

HighSource: Belgium CBE — registered entity data, enterprise 0427.348.346 (Status: Active)

Incorporation / Formation Date1985-05-18 (registry start date; founded 1985 as a University of Liège spin-off; legal form public limited company since 1987-04-24)

HighSource: Belgium CBE — registered entity data (start date May 18, 1985)

Named Principals / ManagersLieven Janssens — CEO (per the company's June 2025 press release). Parent: Kaneka Corporation (majority stake acquired 2010)

ModerateSource: EIN Presswire — Kaneka Eurogentec mRNA facility expansion (Jun 30, 2025), quoting CEO Lieven Janssens

Registered AgentNot independently verified

UnknownSource: Belgium CBE — registered entity data (no registered-agent field exists)

Operating AddressLIEGE Science Park, 5 Rue Bois Saint-Jean, 4102 Seraing, Belgium (registered seat; at this address since 2008-01-04 per the CBE registry)

HighSource: Belgium CBE — registered entity data (registered seat, Rue du Bois St-Jean 5, 4102 Seraing)

Address ConsistencyConsistent — the Seraing address (5 Rue Bois Saint-Jean, 4102 Seraing) is identical across the federal enterprise registry, the company's terms of sale, its website footer and its press releases

HighSource: Belgium CBE — registered entity data; Kaneka Eurogentec GTC Art. 1.1

Domain and Digital Identity#

Domain Registration Date1999-01-05

HighSource: Verisign RDAP — eurogentec.com

Domain Ownership / Registrar Change HistoryCurrent registrar Network Solutions, LLC; RDAP record last changed 2021-11-06. Earlier registrar/ownership change history was not retrieved in this pass

ModerateSource: Verisign RDAP — eurogentec.com

Website ContinuityContinuity supported — domain registered 1999-01-05 for a company founded in 1985; the site carries current operational content, including General Terms amended 2025-10-14 and a June 2025 facility-expansion announcement

HighSource: Verisign RDAP — eurogentec.com; Kaneka Eurogentec GTC (latest amendment Oct 14, 2025)

Contact Channel IntegrityPublished corporate channels: info@eurogentec.com, +32 4 372 74 00, registered-office address in Seraing — identical across the site footer, the terms of sale and the Belgian federal registry record

HighSource: Kaneka Eurogentec — site FAQ footer (address, email, phone); Belgium CBE registry record

Regulatory and Legal History#

FDA Warning Letter HistoryNo Record Found in the defined search

HighSource: Defined web search of FDA warning letters — no letter naming Eurogentec/Kaneka Eurogentec

FDA Recall / Safety Action HistoryNo Record Found in the defined search

HighSource: Defined web search of FDA recalls — no recall naming Eurogentec

FDA Import Alert / Detention ExposureNo Record Found in the defined search

ModerateSource: Defined web search of FDA import alerts — no alert naming Eurogentec

FTC Enforcement HistoryNo Record Found in the defined search

HighSource: Defined web search of FTC enforcement — no action naming Eurogentec

State Regulatory / Attorney General ActionsNo Record Found in the defined search

ModerateSource: Defined web search of state AG/regulatory actions — none naming Eurogentec

Relevant Civil LitigationNo Record Found in the defined search

ModerateSource: Defined web search of litigation involving Eurogentec — none found

Criminal / Injunctive ProceedingsNo Record Found in the defined search

ModerateSource: Defined web search of criminal/injunctive proceedings — none naming Eurogentec

Testing and COA Evidence#

Public COA AvailabilityCertificates of Analysis are provided with peptide orders rather than posted in a public lot library: the company's published GMP-vs-research grade comparison lists a Certificate of Analysis for both grades, and its peptide FAQ states that catalog-peptide QC datasheets list appearance, % peak area by analytical HPLC, identity by MS and solubility, with raw data available on request

ModerateSource: Kaneka Eurogentec — GMP peptide manufacturing page (grade comparison table)

Batch / Lot SpecificityLot/batch-specific for GMP grade: the vendor's published grade comparison lists a batch manufacturing record and review, a retained lot sample, a product specification and a CoA for GMP-grade peptides (research grade: CoA and specification)

ModerateSource: Kaneka Eurogentec — GMP peptide manufacturing page (GMP vs research grade table)

Independent Laboratory IdentityNo independent third-party laboratory is named; peptide QC (analytical HPLC, mass spectrometry) is performed in-house at the Seraing, Belgium site, with GMP peptide/API capability also at the group's U.S. subsidiary AnaSpec (Fremont, CA)

ModerateSource: Kaneka Eurogentec — Peptides FAQ (QC datasheet contents)

COA Verification StatusCoA/QC documentation is vendor-issued and supplied with orders or on request; no independent public verification portal was found. GMP-grade peptides are produced under 21 CFR Parts 210/211 quality controls per the vendor's published grade comparison

ModerateSource: Kaneka Eurogentec — GMP peptide manufacturing page (quality systems controls)

Test RecencyNot independently verified

UnknownSource: Kaneka Eurogentec — Peptides FAQ (QC performed per product; no dated public results)

Testing CoverageDocumented coverage: catalog-peptide QC datasheets report appearance, % peak area by analytical HPLC, identity by MS and solubility (raw data on request; additional attributes as a fee-for-service). Custom/GMP peptides add analytical method development, stability programs and ICH-style forced-degradation studies for IND-support packages; peptide purity is stated at 95% by HPLC unless otherwise specified

HighSource: Kaneka Eurogentec — Peptides FAQ (QC datasheet attributes)

Evidence ConsistencyConsistent — entity name, enterprise number, Seraing address, 1985 founding and Kaneka ownership agree across the Belgian federal enterprise registry, the company's terms of sale, press releases and trade sources. One recurring secondary-source error is corrected here: Kaneka took its majority stake in 2010 and the 2017 event was the rename to Kaneka Eurogentec (some sources mislabel 2017 as the acquisition)

ModerateSource: Belgium CBE registry; INOVIO/Kaneka Eurogentec release ('became part of Kaneka in 2010, renamed April 2017')

Payment, Refund and Shipping#

Accepted Payment MethodsNot independently verified

UnknownSource: Kaneka Eurogentec — General Terms & Conditions of Sale, Art. 1.2 (B2B-only scope)

Refund / Return PolicyNot independently verified

UnknownSource: Kaneka Eurogentec — General Terms & Conditions of Sale (rev. Oct 14, 2025)

Shipping & Fulfillment RepresentationsB2B fulfillment with order tracking: the company's order FAQ states customers can view order, payment and delivery status and carrier tracking numbers in their account. Manufacturing is in Belgium (Seraing/Liège) with U.S. peptide operations via subsidiary AnaSpec; no consumer-style delivery promises are made

ModerateSource: Kaneka Eurogentec — Order FAQ (order history, delivery status, tracking)

Terms / Policy StabilityPublished General Terms & Conditions of Sale carry a stated latest-amendment date (October 14, 2025) and apply to all offers and sales of Kaneka Eurogentec S.A. and its subsidiaries/branches — versioned, stable B2B terms

HighSource: Kaneka Eurogentec — General Terms & Conditions of Sale (latest amendment Oct 14, 2025)

Customer Complaint PatternNo Record Found in the defined search

ModerateSource: Defined web search for Eurogentec complaints/reviews — no pattern found

Material Changes#

No material changes recorded.

Sources#

Belgium Crossroads Bank for Enterprises (CBE) — registered entity data, enterprise 0427.348.346Tier 1 · AuthoritativeSos Business SearchAuthoritative

Retrieved: October 20, 2026